ABBV-295 vs cagrilintide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin receptor · full Obesity pipeline

ABBV-295

Developed by AbbVie under a licence from Gubra

Phase 2 in Obesitypeptide
Weak signal

NCT06144684 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety - Adverse Events (AE) incidence" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07514260 (registry estimate)

Reported efficacy

Safety - Adverse Events (AE) incidence (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - changes in vital signs (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - Safety laboratory parameters (From baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C): Two-part first-in-human phase 1 study of subcutaneous ABBV-295, a long-acting amylin analog: ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels and no serious adverse events were reported. Treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 with weekly dosing. (not_applicable)

Result source: NCT06144684

cagrilintide

Developed by Novo Nordisk

Phase 3 in Obesitypeptide
Reliable signal

NCT03856047 · Phase 2 · completed

The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.

Next expected readout: January 2027 · NCT07411560 (registry estimate)

Reported efficacy

Change in Body Weight (%) (From baseline (week 0) to week 26): Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2) (met)

Result source: NCT03856047

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointABBV-295cagrilintide
Body weight, % change—Not reported-10.8% vs -3%−7.8 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -9.5% vs -3% 2.4 mg · wk 26 · n 99 · Phase 2 · primary NCT03856047
  • -8.5% vs -3% 1.2 mg · wk 26 · n 98 · Phase 2 · primary NCT03856047
  • -6.9% vs -3% 0.6 mg · wk 26 · n 97 · Phase 2 · primary NCT03856047
  • -6.1% vs -3% 0.3 mg · wk 26 · n 96 · Phase 2 · primary NCT03856047
Weight loss of 5% or more—Not reported88.7% vs 30.9%+57.8 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 74.1% vs 30.9% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 75.8% vs 30.9% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 62.0% vs 30.9% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 57.5% vs 30.9% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
Weight loss of 10% or more—Not reported53.5% vs 10.4%+43.1 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 44.0% vs 10.4% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 35.8% vs 10.4% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 24.1% vs 10.4% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 15.3% vs 10.4% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
Waist circumference, change (cm)—Not reported-9.5 vs -3.4−6.1 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -8.1 vs -3.4 2.4 mg · wk 26 · n 99 · Phase 2 · secondary NCT03856047
  • -7.7 vs -3.4 1.2 mg · wk 26 · n 98 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.6 mg · wk 26 · n 97 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.3 mg · wk 26 · n 96 · Phase 2 · secondary NCT03856047

Body weight, % change

ABBV-295
—Not reported
cagrilintide
-10.8% vs -3%−7.8 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -9.5% vs -3% 2.4 mg · wk 26 · n 99 · Phase 2 · primary NCT03856047
  • -8.5% vs -3% 1.2 mg · wk 26 · n 98 · Phase 2 · primary NCT03856047
  • -6.9% vs -3% 0.6 mg · wk 26 · n 97 · Phase 2 · primary NCT03856047
  • -6.1% vs -3% 0.3 mg · wk 26 · n 96 · Phase 2 · primary NCT03856047

Weight loss of 5% or more

ABBV-295
—Not reported
cagrilintide
88.7% vs 30.9%+57.8 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 74.1% vs 30.9% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 75.8% vs 30.9% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 62.0% vs 30.9% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 57.5% vs 30.9% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047

Weight loss of 10% or more

ABBV-295
—Not reported
cagrilintide
53.5% vs 10.4%+43.1 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 44.0% vs 10.4% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 35.8% vs 10.4% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 24.1% vs 10.4% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 15.3% vs 10.4% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047

Waist circumference, change (cm)

ABBV-295
—Not reported
cagrilintide
-9.5 vs -3.4−6.1 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -8.1 vs -3.4 2.4 mg · wk 26 · n 99 · Phase 2 · secondary NCT03856047
  • -7.7 vs -3.4 1.2 mg · wk 26 · n 98 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.6 mg · wk 26 · n 97 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.3 mg · wk 26 · n 96 · Phase 2 · secondary NCT03856047
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ABBV-295: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ABBV-295: 0 of 4 rows · cagrilintide: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccagrilintide
Dropout rate
6.9%4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
1%2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
3.9%1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
3%0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
4%0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Discontinued due to AEs
—4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
—2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Serious AEs
4%4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
2.9%2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
6.9%1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
2%0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
5.9%0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Most frequent reported AEs
4.5 mg
nausea 46.5% (placebo 17.8%)
constipation 20.8% (placebo 6.9%)
fatigue 19.8% (placebo 3%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
2.4 mg
nausea 31.4% (placebo 17.8%)
diarrhoea 17.6% (placebo 8.9%)
constipation 16.7% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
1.2 mg
nausea 36.3% (placebo 17.8%)
nasopharyngitis 12.7% (placebo 9.9%)
headache 10.8% (placebo 11.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0.6 mg
nausea 27% (placebo 17.8%)
diarrhoea 10% (placebo 8.9%)
constipation 9% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0.3 mg
nausea 19.8% (placebo 17.8%)
diarrhoea 14.9% (placebo 8.9%)
constipation 10.9% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

cagrilintide

Weight -10.8% (n=97) vs -3% (n=95) placebo @ 26wk4.5 mg
percent change · % of baseline
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-9.5% (n=99) vs -3% (n=95) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-8.5% (n=98) vs -3% (n=95) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.9% (n=97) vs -3% (n=95) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.1% (n=96) vs -3% (n=95) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 5% 88.74% (n=80) vs 30.9% (n=79) placebo @ 26wk4.5 mg
responder rate · % of participants
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
74.12% (n=80) vs 30.9% (n=79) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
75.84% (n=72) vs 30.9% (n=79) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
61.98% (n=82) vs 30.9% (n=79) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
57.47% (n=83) vs 30.9% (n=79) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 10% 53.49% (n=80) vs 10.44% (n=79) placebo @ 26wk4.5 mg
responder rate · % of participants
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
43.97% (n=80) vs 10.44% (n=79) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
35.79% (n=72) vs 10.44% (n=79) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
24.06% (n=82) vs 10.44% (n=79) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
15.28% (n=83) vs 10.44% (n=79) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Weight -11.8 vs -3.2 placebo kg @ 26wk4.5 mg
absolute change · kg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-10.1 vs -3.2 placebo kg @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-9 vs -3.2 placebo kg @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-7.1 vs -3.2 placebo kg @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.6 vs -3.2 placebo kg @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Waist Circumference Change -9.5 vs -3.4 placebo cm @ 26wk4.5 mg
absolute change · cm
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-8.1 vs -3.4 placebo cm @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-7.7 vs -3.4 placebo cm @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.2 vs -3.4 placebo cm @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.2 vs -3.4 placebo cm @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
HbA1c -0.1% (n=95) vs -0.1% (n=94) placebo @ 26wk4.5 mg
absolute change · percentage points
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-0.1% (n=99) vs -0.1% (n=94) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-0.1% (n=95) vs -0.1% (n=94) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-0.1% (n=97) vs -0.1% (n=94) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0% (n=93) vs -0.1% (n=94) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-295's landscape · cagrilintide's landscape